October 22, 2014 / 12:15 PM / 6 years ago

Abbott says third-quarter sales match forecasts

Oct 22 (Reuters) - Abbott Laboratories said its third-quarter sales were in line with Wall Street forecasts and that it had slightly changed the terms of a deal to sell generic drugs to Mylan Inc.

Abbott on Wednesday said sales from continuing and discontinued operations rose 4.7 percent to $5.6 billion in the third quarter. That included generic medicines, now considered discontinued products, which will be sold to Mylan.

Reporting by Ransdell Pierson; Editing by Lisa Von Ahn

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below